Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Status:
Completed
Trial end date:
2018-04-17
Target enrollment:
Participant gender:
Summary
Trial objectives:
To decide whether the addition of nelfinavir to the approved antimyeloma therapy with
bortezomib and dexamethasone has sufficient activity in proteasome inhibitor-resistant
myeloma patients to merit further clinical investigation in a prospective controlled trial.
Additional research questions:
To collect myeloma cell samples from proteasome inhibitor-resistant myeloma patients for the
assessment of the biology of proteasome inhibitor resistance and the identification of
predictive markers for response to nelfinavir-based antimyeloma therapy.